Scarica l'app Stockscreener
496.83
3.48%
16.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$480.13
Aprire:
$480.31
Volume 24 ore:
1.78M
Relative Volume:
1.24
Capitalizzazione di mercato:
$126.21B
Reddito:
$12.07B
Utile/perdita netta:
$3.95B
Rapporto P/E:
32.40
EPS:
15.3349
Flusso di cassa netto:
$3.19B
1 W Prestazione:
+4.18%
1M Prestazione:
+4.78%
6M Prestazione:
+27.69%
1 anno Prestazione:
+4.71%
Intervallo 1D:
$479.75
$497.80
Intervallo di 1 settimana:
$474.59
$497.80
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Intech Investment Management LLC Has $13.46 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
TD Asset Management Inc Sells 247,634 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Erste Asset Management GmbH Has $26.69 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 58,613 Shares of Stock - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Holdings Raised by Banco Santander S.A. - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 1,846 Shares of Stock - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Ourania Tatsis Sells 260 Shares - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) CAO Kristen Ambrose Sells 223 Shares - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Mark Bunnage Sells 620 Shares - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 4,910 Shares of Stock - MarketBeat
Vertex Pharmaceuticals EVP Sachdev sells $897k in shares By Investing.com - Investing.com Canada
Vertex Pharma EVP McKechnie sells $2.39m in shares By Investing.com - Investing.com Nigeria
Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuti - GuruFocus
Vertex Pharmaceuticals EVP Tatsis sells $126k in stock - Investing.com UK
2 Top Healthcare Stocks to Buy in February - The Motley Fool
Daiwa Securities Adjusts Vertex Pharmaceuticals PT to $561 From $500, Maintains Buy Rating - marketscreener.com
Vertex Pharma Stock: Is Wall Street Too Cautious After The Neuropathy Surprise? - AD HOC NEWS
Vertex Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
First American Trust FSB Has $1.16 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
DC Circ. Talks Sharks, Moats In Vertex HHS Kickback Appeal - Law360
Kovitz Investment Group Partners LLC Boosts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Forget AI and Weight-Loss Drugs: Why Vertex Pharmaceuticals Is the Silent Compounder You Need - NAI500
Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036? - The Globe and Mail
Lansforsakringar Fondforvaltning AB publ Increases Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bowen Hanes & Co. Inc. Sells 56,365 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Tredje AP fonden Sells 65,290 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Mitsubishi UFJ Asset Management UK Ltd. Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Jupiter Asset Management Ltd. Invests $25.70 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Insulet (PODD) - The Globe and Mail
HighTower Advisors LLC Sells 12,332 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash - AOL.com
Is Vertex Pharmaceuticals (VRTX) Now Offering A Compelling Entry Point After Flat One Year Returns - Yahoo Finance
Insider Sell: Atkinson Edward Morrow III Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Broadens Beyond Cystic Fibrosis As CASGEVY And Pipeline Take Shape - Yahoo Finance
Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales - AlphaStreet News
Mcrae Capital Management Inc. Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cumberland Partners Ltd Has $3.82 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Q4 2025 Earnings: Revenue Beats, Driven by CF Growth & New LaunchesNews and Statistics - IndexBox
5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q4 Earnings Call - Finviz
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call - Yahoo Finance
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 1,500 Shares of Stock - MarketBeat
Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade) (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharmaceuticals (VRTX) Analyst Rating Update: Canaccord G - GuruFocus
Grange Capital LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
PNC Financial Services Group Inc. Has $27.33 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals stock: Is Wall Street bullish or bearish? - MSN
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3 - BioSpace
Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks - MSN
Narrow-Moat Vertex's Strong CF Sales Drive Growth as Non-CF Portfolio Starts to Gain Traction - Morningstar
Vertex Pharmaceuticals (VRTX) Sees Analyst Rating Maintained wit - GuruFocus
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.41%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):